Clinical Trial Update: Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating dasatinib in combination with chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• Sprycel (dasatinib)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Acute,Leukemia, Lymphoid | Phase 2 | Status: COMPLETED